MiR-223 Deficiency Protects Against Fas-Induced Hepatocyte Apoptosis and Liver Injury Through Targeting Insulin-Like Growth Factor 1 Receptor
Overview
Affiliations
The biological functions and molecular mechanisms of miR-223 action in liver cells and liver diseases remain unclear. We therefore determined the effect and mechanism of action of miR-233 in Fas-induced hepatocyte apoptosis and liver injury. Wild-type (WT) and miR-223 knockout (KO) mice were treated i.p. with 0.5 μg/g body weight anti-Fas antibody Jo2, and the animals were monitored for survival and the extent of liver injury. Although WT mice died 4 to 6 hours after Jo2 injection (n = 6), all of the miR-223 KO mice (n = 6) survived. In comparison to WT mice, the miR-223 KO mice showed resistance to Fas-induced liver injury, as indicated by less tissue damage under histopathological examination, fewer apoptotic hepatocytes under caspase-3 immunostaining, and less elevation of serum transaminases. miR-223 KO livers showed less caspase-3, caspase-8, and caspase-9 activation and less poly (ADP-ribose) polymerase cleavage compared with WT livers (P < 0.05). Furthermore, tail vein injection of miR-223 lentiviral vector to miR-223 KO mice restored Jo2-induced liver injury. Transfection of miR-223 KO hepatocytes with miR-223 mimic enhanced Jo2-induced activation of caspase-3, caspase-8, and caspase-9, whereas transfection of WT hepatocytes with the miR-223 inhibitor attenuated Jo2-induced apoptosis. These findings demonstrate that miR-223 deficiency protects against Fas-induced hepatocyte apoptosis and liver injury. Further in vitro and in vivo data indicate that miR-223 regulates Fas-induced hepatocyte apoptosis and liver injury by targeting the insulin-like growth factor 1 receptor.
The effect of SNPs in lncRNA as ceRNA on the risk and prognosis of hepatocellular carcinoma.
Mo H, Wang X, Ji G, Liang X, Yang Y, Sun W BMC Genomics. 2022; 23(1):769.
PMID: 36418931 PMC: 9685961. DOI: 10.1186/s12864-022-09010-9.
Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis.
Matsumoto K, Kato Y, Hayashi M, Miura R, Monzen S, Chiba M Mol Med Rep. 2022; 26(5).
PMID: 36052866 PMC: 9727582. DOI: 10.3892/mmr.2022.12841.
MiR-223 as a Regulator and Therapeutic Target in Liver Diseases.
Gu J, Xu H, Chen Y, Li N, Hou X Front Immunol. 2022; 13:860661.
PMID: 35371024 PMC: 8965842. DOI: 10.3389/fimmu.2022.860661.
Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism.
Nara H, Watanabe R Int J Mol Sci. 2021; 22(18).
PMID: 34576053 PMC: 8471880. DOI: 10.3390/ijms22189889.
MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Fang Z, Dou G, Wang L Int J Biol Sci. 2021; 17(7):1851-1863.
PMID: 33994867 PMC: 8120467. DOI: 10.7150/ijbs.59588.